Sputum, Gotta Love The Stuff!
|
|
- Gladys Pitts
- 5 years ago
- Views:
Transcription
1 Sputum, Gotta Love The Stuff! Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Georgia State University
2 Objectives Differentiate mucus from sputum. Discuss factors associated with abnormal mucus production. Discuss diseases associated with abnormal mucus production. Discuss mucoactive agents. Discuss mucoactive treatments.
3 Overview What is mucus doing for me? Source Factors associated with mucus Mucus and disease vs. Sputum Physical Properties Mucoactive Agents Mucoactive Treatments
4 Mucociliary Escalator Major Defense mechanism Failure Obstruction Thickened adhesive secretions Slowed with disease
5 Mucus.Where and Why Airways Gastrointestinal tract Genital tract Protective Lubricating Waterproofing
6 Source of Airway Secretions Mucus Gel Layer Moved by cilia towards larynx Sol Layer Watery layer below gel layer Produced by Surface epithelial cells Goblet cells Submucosal glands
7 From Gardenhire, D. (2016). Rau s Respiratory Care Pharmacology, Elsevier
8 From Gardenhire, D. (2016). Rau s Respiratory Care Pharmacology, Elsevier
9 Surface Epithelial Cells Surface of Trachea/bronchi Ciliated cells Goblet cells More than 6000 goblet cells per square mm of airway Responds only to irritants Submucosal Glands Produces most of mucus in airway Parasympathetic control Cholinergic Stimulation Possible Sympathetic Innervation
10 From Gardenhire, D. (2016). Rau s Respiratory Care Pharmacology, Elsevier
11 Factors Affecting Mucociliary Transport COPD CF Dry airway (dry gas from MV) Narcotics Suctioning; Trach Cigarette smoke Pollutants Hyperoxia and Hypoxia
12 Food Intake and Mucus Production Does milk or dairy increase mucus? NO No reason to withhold milk from patients with colds, RTI, or chronic disease Pinnock CB, etal Am Rev Respir Dis 141:352, 1990
13 Composition of Mucus 95% water 5% protein
14 Mucus and Disease Chronic Bronchitis Asthma Bronchorrhea Plastic Brochitis Cystic Fibrosis
15 Rogers D, Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007;52(9):1181
16 Chronic Bronchitis Clinically, daily X 3 mon; X 2yrs Hyperplasia goblet cells Goblet cells increase in number Submucosal glands hypertrophy Tobacco smoke; # 1 irritation factor Cause; mucus hypersecretion Associated with rapid decline in lung function Rubin BK, etal. Clin Pulm Med 5:1, 1998; Vestbo J, etal Am J Respir Crit Care Med 153:1530, 1996.
17 Asthma Hypersecretion can occur during exacerbation 80% of all patient report increased sputum Beta agonists on board- Problem? Beta agonists cause hypersecreation IV/Continuous nebulization Fatality? Turner-Warwick M. etal. Postgrad Med J 63(suppl 1):79, Rubin BK, Pediatr Pulmonol Suppl 23:88, Webber SE, etal. Agents Actions 22:82, 1987.
18 Bronchorrhea Clinically 100 ml of watery sputum daily Occurs in about 9% of asthmatics Treat with corticosteroids and/or antibiotics Shimura S, etal. Chest 94:1211, 1988; Marom ZM, etal. J Allergy Clin Immunol 87:1050, 1991.
19 Plastic Bronchitis Rare, Clinically, rigid airway casts Patients may cough up casts of the TB Tree May be toothpaste or pudding-like Madsen P, Shah SA, Rubin BK: Paediatr Respir Rev 6:292, 2005.
20 Cystic Fibrosis Chronic hereditary disease Impaired function of CFTR protein Chronic airway infection with Pseudomonas and other gram bacteria Chronic airway inflammation NO hypersecretion of airway Very little to no mucus in sputum Airway filled with PUS Similar sputum to bronchiectasis Bush A, Payne D, Pike S, Jenkins G, Henke MO, Rubin BK: Chest 129:118, 2006.
21 Physical Properties of Mucus Mucus (low viscosity, high elasticity ) Sputum (viscosity increases) From Gardenhire, D. (2016)Rau s Respiratoy Care Pharmacology, Elsevier
22 Mucoactive Agents
23 N-ACETYL L-CYSTEINE (NAC) Reduce hepatic injury with acetaminophen overdose Long history of use No evidence of clinical efficacy Inhaled NAC can cause bronchospasm Breaks down mucus, not sputum Difference between mucus & sputum Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R et al.: Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial, Lancet 365 (9470): , 2005.
24 Rogers D, Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007;52(9):1181
25 Dornase Alfa (Pulmozyme) Reduces DNA and F-actin polymers Shak s, etal Proc Natl Acad Sci USA 98:9188, 1990 No efficacy in acute exacerbations No efficacy in non-cf bronchietasis Wilmott RW, etal Am J Respir Crit Care Med 153:1914, 1996 May decrease effectiveness of aminoglycosides Ramsey BW, etal Pediatr Pulmonol 17:404, 1994
26 Courtesy Bruce K. Rubin, From Gardenhire D, (2016) Rau s Respiratory Care Pharmacology, Elsevier
27 Expectorants
28 Iodide Containing Agents Supersaturated Potassium Iodide (SSKI) Stimulate airway fluid secretion Has failed to makes changes to PFT or sputum Rubin B, etal Chest 109:348, 1996
29 Sodium Bicarbonate Tracheal instillation or Inhalation 2% concentration Increases bronchial ph Breaks bonds, decreasing viscosity and elasticity Not clinically shown to increase mucus clearance From Gardenhire D, (2008) Rau s Respiratory Care Pharmacology, Mosby
30 Guaifenesin Can be toxic to cilia if directly applied Works by stimulation of submucosal gland Increases mucus production Not been demonstrated to be effective, clinically Rubin BK, etal. Chest 116:195, 1999
31 Mucus Why Protective Lubricating Waterproofing
32 Oligosaccharides Oligosaccharides side chains make up 80% of mucus Aerosolized low wt molecular heparin Used in treatment of asthma Interferes with antigen-receptor binding Disrupting H+ bond Same thought for use of aerosolized mannitol and dextran Ahmed T, etal. N Engl J Med 329:90, 1993
33
34 Mucokinetics
35 Bronchodilators Beta-agonists Produce mucus, can cause problems Mucus trapping, fatal asthma Work best by increasing airflow Newhouse, MT Euro J Respir Dis Suppl 124:151, 1983
36 Other
37 Hyperosmolar Saline 6% saline increased CF patients PFT Shown to improve PFTs in CF and non-cf bronchiectasis patients. Daviskas E. etal. Respirology 10:46, 2005 Mannitol has been effective in non-cf bronchiectasis patients Wills P, etal. Cochrane Database Syst Rev 3: CD001506, 2006 Not as effective as dornase alfa in CF Suri R, etal. Lancet 358:1316, 2001 Due to cough induction, aerosolized antibiotic therapy must be last!
38 Hypertonic Saline 7% hypertonic solution Commonly used in CF Believed to increase FEV1 by decreasing mucus Pulmosal FDA-cleared, buffered with sodium bicarbonate to a ph of 7.4. Others are acidic ph of 4.5 to 7.0 Pseudomonas aeruginosa has an affinity to colonize in an acidic ph of ~6.0.
39 PulmoSal vs. Hypertonic Saline
40 Mucoactive Therapy
41 Physiotherapy and Breathing Gravity Best if added to conventional CPT Mucus blanket can resist gravity alone GERD is a major problem Thomas J, etal. Am J Respir Crit Care Med 151:846, 1995 Breathing techniques Active cycle breathing (ACB) Diaphragmatic breathing with deep breaths Forced expiratory technique (FET) Huff cough with glottis open Hansani A, etal. Chest 105:1420, 1994 Exercise Increases sputum production Bilton, D, etal. Thorax 44:859, 1989
42 Insufflation-Exsufflation Stimulates cough with + and pressure Bach JR, Chest 105:1538, 1994
43 Positive Airway Pressure PEP Pursed lip breathing More effective than IS or IPPB Ricksten, SE, etal. Chest 89:774, 1986
44 Oscillation of the Airway Flutter Little research done 3 times more sputum in CF than cough or PD Konstan MW, etal. J Pediatr 124:689, 1994 Not confirmed or effective Homnick DN, etal. Chest 114:993, 1998 App EM, etal. Chest 114:171, 1998 Acapella Lung Flute Effective for sputum sampling Quake Generates vibrations on inhalation and exhalation
45 Lung Flute
46 Chest Wall Oscillation Vest Effective in CF Kluf J, etal. Pediatr Pulmonol 22:271, 1996 Not established in non-cf patients
47 HFCWO
48 Summary Difference between Mucus and Sputum Sputum becomes more viscid Mild does not thicken secretions A number of different solution available CPT is a gold standard Use exercise NAC does not work on pulmonary sputum Pulmozyme is only used for CF
49 Questions, Comments, Happy Thoughts?
Chapter 9. Mucus-controlling Drug Therapy. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 9 Mucus-controlling Drug Therapy Drug Control of Mucus: A Perspective Mucociliary escalator is a major defense system Failure may result in mechanical obstruction of the airway Properties of mucus
More informationDisclaimer. Objectives. I can t cough it up! Airway Clearance Therapy. Heather Murgatroyd, RRT, RPSGT Field Clinical Specialist
I can t cough it up! Airway Clearance Therapy Heather Murgatroyd, RRT, RPSGT Field Clinical Specialist 1 Disclaimer Name of presenter: Heather Murgatroyd, BA, RRT, RPSGT Name of employer: RespirTech I
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationTerminology. Terminology. Terminology. Mucus in Disease States. Mucus in Disease States. RSPT 2317 Mucoactive agents. RSPT 2217 Mucoactive Agents
Terminology RSPT 2217 Mucoactive Agents Gardenhire Chapter 9 Mucus secretion from mucous membranes, including surface goblet cells and submucosal glands Sputum expectorated secretions that contain respiratory
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationCYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions
CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions Issue 1: Hypertonic Saline Summary: Preserving lung function is a crucial element in the care of the individual with
More informationThe pharmacologic approach to airway clearance: Mucoactive agents
Rubin. Mucoactive medications. Page # 1 The pharmacologic approach to airway clearance: Mucoactive agents Bruce K. Rubin, MEngr, MD, MBA, FRCPC Professor and Vice-Chair of Pediatrics Professor of Biomedical
More informationBronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago
Bronchiectasis Grant Waterer MBBS PhD MBA FRACP FCCP Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago Conflicts of Interest I have
More information4.6 Small airways disease
4.6 Small airways disease Author: Jean-Marc Fellrath 1. INTRODUCTION Small airways are defined as any non alveolated and noncartilaginous airway that has an internal diameter of 2 mm. Several observations
More informationOverview of Cystic fibrosis in children. Apeksha Sathyaprasad, MD Pediatric pulmonologist
Overview of Cystic fibrosis in children Apeksha Sathyaprasad, MD Pediatric pulmonologist No conflicts of interest OBJECTIVES Review pathophysiology of pulmonary disease in cystic fibrosis Review diagnostic
More informationWorth Its SALT? Hypertonic Saline Revisited
Worth Its SALT? Hypertonic Saline Revisited 1 NYC Long Island Michael McPeck, RRT FAARC Aerosol Research Scientist Aerosol Laboratory Division of Pulmonary, Critical Care & Sleep Medicine State University
More informationChronic Obstructive Pulmonary Disease (COPD) Copyright 2014 by Mosby, an imprint of Elsevier Inc.
Chronic Obstructive Pulmonary Disease () 8.18.18 Copyright 2014 by Mosby, an imprint of Elsevier Inc. Description Airflow limitation not fully reversible progressive Abnormal inflammatory response of lungs
More informationThe objectives of this presentation are to
1 The objectives of this presentation are to 1. Review the mechanics of airway clearance 2. Understand the difference between secretion mobilization and secretion clearance 3. Identify conditions that
More informationCystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS
Cystic Fibrosis Jennifer McDaniel, BS, RRT-NPS Overview Cystic fibrosis is the most common fatal, inherited disease in the U. S. CF results from a defective autosomal recessive gene One copy of gene =
More informationDean R Hess PhD RRT FAARC
Conference Summary Airway Clearance: Physiology, Pharmacology, Techniques, and Practice Dean R Hess PhD RRT FAARC Introduction Physiology Pharmacology Techniques Practice What to Do? Summary Clinicians
More informationWhat is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF
What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic
More informationA Place For Airway Clearance Therapy In Today s Healthcare Environment
A Place For Airway Clearance Therapy In Today s Healthcare Environment Michigan Society for Respiratory Care 2015 Fall Conference K. James Ehlen, MD October 6, 2015 Objectives Describe patients who will
More informationPulmo-Park Pom-Pom Shooter: Measuring the Effect of Restricted Breathing on Peak Expiratory Flow (PEF) Student Information Page Activity 5D
Pom-Pom Shooter: Measuring the Effect of Restricted Breathing on Peak Expiratory Flow (PEF) Student Information Page Activity 5D Students with asthma or other respiratory problems should not perform the
More informationSystems Pharmacology Respiratory Pharmacology. Lecture series : General outline
Systems Pharmacology 3320 2017 Respiratory Pharmacology Associate Professor Peter Henry (Rm 1.34) Peter.Henry@uwa.edu.au Division of Pharmacology, School of Biomedical Sciences Lecture series : General
More informationBronchitis. Anatomy of the Lungs The lungs allow us to fill our blood with oxygen. The oxygen we breathe is absorbed into our blood in the lungs.
Bronchitis Introduction Bronchitis is an inflammation of the bronchial tubes, the airways that carry air to the lungs. It causes shortness of breath, wheezing and chest tightness as well as a cough that
More informationFocus on Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis
Focus on (Relates to Chapter 29, Nursing Management: Obstructive Pulmonary Diseases, in the textbook) Copyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Autosomal recessive, multisystem
More informationPharmacologic Agents That Promote Airway Clearance in Hospitalized Subjects: A Systematic Review
Pharmacologic Agents That Promote Airway Clearance in Hospitalized Subjects: A Systematic Review Nila A Sathe MA MLIS, Shanthi Krishnaswami MBBS MPH, Jeff Andrews MD, Cathy Ficzere PharmD BCPS, and Melissa
More informationMEDICAL POLICY. Proprietary Information of Excellus Health Plan, Inc. A nonprofit independent licensee of the BlueCross BlueShield Association
MEDICAL POLICY SUBJECT: AIRWAY CLEARANCE DEVICES: OSCILLATORY DEVICES (e.g. High frequency MECHANICAL PERCUSSORS AND ASSISTED 04/15/04, 04/21/05, 02/16/05, PAGE: 1 OF: 8 If a product excludes coverage
More informationan inflammation of the bronchial tubes
BRONCHITIS DEFINITION Bronchitis is an inflammation of the bronchial tubes (or bronchi), which are the air passages that extend from the trachea into the small airways and alveoli. Triggers may be infectious
More informationPomPom SHOOTER. Activity Background: Common Obstructive Lung Disorders:
CAUTION: Students with asthma or other respiratory problems should NOT perform the breathing exercises in this activity because they involve repeated maximal inhalations and exhalations and use of a breathing
More informationProtocol. Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions
Oscillatory Devices for the Treatment of Cystic Fibrosis and Other (10115) Medical Benefit Effective Date: 01/01/18 Next Review Date: 07/18 Preauthorization No Review Dates: 01/07, 03/08, 03/09, 03/10,
More informationGoals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy
CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy What is Cystic Fibrosis? Chronic, progressive
More informationPATHOPHYSIOLOGICAL PROCESS TEMPLATE
1 PATHOPHYSIOLOGICAL PROCESS TEMPLATE DISEASE: Chronic obstructive pulmonary disease (COPD) DEFINITION: COPD can be defined as a disease in which there is a significant damage to the lungs thus reducing
More informationCystic Fibrosis the future
Cystic Fibrosis the future Pathophysiologic cascade Abnormal Gene Abnormal CFTR Therapy Gene replacement Protein replacement Gene read through therapy Abnormal sodium chloride & water movement through
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease By: Dr. Fatima Makee AL-Hakak () University of kerbala College of nursing Out lines What is the? Overview Causes of Symptoms of What's the difference between and asthma?
More informationINHALED MUCOACTIVE DRUGS FOR TREATING NON-CYSTIC FIBROSIS BRONCHIECTASIS IN CHILDREN
I.iTER.iATlO.iAL JOl R:'I
More informationNon Cystic Fibrosis Bronchiectasis: How to Proceed?
Non Cystic Fibrosis Bronchiectasis: How to Proceed? Dr Ankit Parakh MD, DNB, MNAMS, RCPCH Fellow (UK), European Diplomate of Pediatric Respiratory Medicine ERS Fellowship Pediatric Medicine & NIV (GOSH,
More informationRESPIRATORY REHABILITATION
RESPIRATORY REHABILITATION By: Dr. Fatima Makee AL-Hakak University of kerbala College of nursing CHEST PHYSIOTHERAPY Chest physiotherapy (CPT) includes: 1.Postural drainage. 2.Chest percussion and vibration.
More informationSection: Durable Medical Equipment Last Reviewed Date: June Policy No: 45 Effective Date: September 1, 2014
Medical Policy Manual Topic: Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Disorders Date of Origin: May 26, 2011 Section: Durable Medical Equipment Last Reviewed Date:
More informationBronchiectasis. Examples include: Viral infections (measles, adenovirus, influenza)
Bronchiectasis What is Bronchiectasis? Bronchiectasis (pronounced bron-kee-ek'-tas-is) is a condition of the airways in the lungs. These airways (bronchial tubes) are tubelike structures that branch from
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: October 15, 2018 Related Policies: None Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Description Oscillatory devices are alternatives to
More informationCOPD. Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS
IN THE NAME OF GOD COPD Dr.O.Paknejad Pulmonologist Shariati Hospital TUMS Definition of COPD* COPD is a preventable and treatable chronic lung disease characterized by airflow limitation that is not fully
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationLevine Children s Hospital. at Carolinas Medical Center. Respiratory Care Department
Page 1 of 7 at Carolinas Medical Center 02.04 Pediatric Patient-Centered Respiratory Care Protocol Application of Chest Physical Therapy Created: 1/98 Reviewed: 4/03, 1/05, 6/08 Revised: Purpose: To describe
More informationChapter 10 Respiration
1 Chapter 10 Respiration Introduction/Importance of the Respiratory System All eukaryotic organisms need oxygen to perform cellular respiration (production of ATP), either aerobically or anaerobically.
More informationBronchiectasis. Introduction. Key points
15 Bronchiectasis Introduction i Key points Patients with bronchiectasis typically have chronic airway infection, punctuated by acute exacerbations and accompanied by progressive airflow obstruction. Bronchiectasis
More informationChronic obstructive lung disease. Dr/Rehab F.Gwada
Chronic obstructive lung disease Dr/Rehab F.Gwada Obstructive lung diseases Problem is in the expiratory phase Lung disease Restrictive lung disease Restriction may be with, or within the chest wall Problem
More informationCystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel
Cystic fibrosis: From childhood to adulthood Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Vas deference H 2 O Cl - Na + H 2 O Na + Cl - Cl - Cl -
More informationPharmacological airway clearance strategies in bronchiectasis
Chapter 16 Pharmacological airway clearance strategies in bronchiectasis P.T. Bye*,#,", E.M.T. Lau*,#," and M.R. Elkins*," Summary Impaired mucociliary clearance and mucus retention contribute to the chronic
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationIntegrated Cardiopulmonary Pharmacology Third Edition
Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive
More informationCorporate Medical Policy
Corporate Medical Policy Oscillatory Devices for the Treatment of Respiratory Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: oscillatory_devices_for_treatment_of_respiratory_conditions
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationRespiratory Pharmacology: Treatment of Cystic Fibrosis
Respiratory Pharmacology: Treatment of Cystic Fibrosis Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationCOPD COPD. C - Chronic O - Obstructive P - Pulmonary D - Disease OBJECTIVES
COPD C - Chronic O - Obstructive P - Pulmonary D - Disease 1 OBJECTIVES Following this presentation the participant should be able to demonstrate understanding of chronic lung disease by successful completion
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationCOPD: Change in Definition. COPD Pathology with 3D Interactive. COPD: Definitions of 21st Century 1. COPD Includes Chronic Bronchitis 2
COPD: Change in Definition COPD Pathology with 3D Interactive by Scott Cerreta, BS, RRT Director of Education www.copdfoundation.org COPD used to include 5 disease processes 1 1 Chronic Bronchitis 2 Emphysema
More informationRESPIRATORY DISORDERS
RESPIRATORY DISORDERS INTRODUCTION Respiratory disorders refers to the medical term that include different pathological conditions affecting the organs and tissues of respiratory system which make gas
More informationPulmonary Exacerbations:
Pulmonary Exacerbations: Better Understanding Needed Michael Tracy, MD Clinical Assistant Professor Pediatric Pulmonary CF Pulmonary Exacerbations Definition Importance Causes Treatment Research opportunities
More informationRespiratory Anesthetic Emergencies in Oral and Maxillofacial Surgery. By: Lillian Han
Respiratory Anesthetic Emergencies in Oral and Maxillofacial Surgery By: Lillian Han Background: Respiratory anesthetic emergencies are the most common complications during the administration of anesthesia
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationBY BILL PRUITT, RRT, AE-C, CPFT, MBA, AND MICHAEL JACOBS, RN, CCRN, CEN, MSN
C E 2.5 ANCC/AACN CONTACT HOURS Clearing away pulmonary secretions Excess or retained pulmonary secretions impair ventilation, invite infection, and may threaten survival. Find out who s at greatest risk
More informationOver the last several years various national and
Recommendations for the Management of COPD* Gary T. Ferguson, MD, FCCP Three sets of guidelines for the management of COPD that are widely recognized (from the European Respiratory Society [ERS], American
More informationChapter 7. Anticholinergic (Parasympatholytic) Bronchodilators. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 7 Anticholinergic (Parasympatholytic) Bronchodilators Clinical Indications for Use Indication for anticholinergic bronchodilator COPD maintenance Indication for combined anticholinergic and β-agonist
More informationRole of mucolytics in the management of COPD
REVIEW Role of mucolytics in the management of COPD Phillippa J Poole University of Auckland, Auckland, New Zealand Abstract: There is, to date, no medical therapy that modifies the decline in lung function
More informationTreatment of Cough. Cough is a useful protective reflex. Cough is an indicator of an underlying illness.
Treatment of Cough Cough is a useful protective reflex. Cough is an indicator of an underlying illness. Mechanical stimulation of large respiratory passages, OR: Chemical stimulation of alveoli. After
More informationClinical Commissioning Policy: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)
Clinical Commissioning Policy: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages) Reference: NHS England: 16029/P NHS England INFORMATION READER BOX Directorate Medical Operations and
More informationChronic respiratory disease: towards better treatments
Chronic respiratory disease: towards better treatments Alaina J. Ammit PhD Alaina.Ammit@uts.edu.au Professor of Respiratory Pharmacology, UTS Director, Woolcock Emphysema Centre, Woolcock Institute of
More informationTreatment of Cough. Cough is a useful protective reflex. Cough is an indicator of an underlying illness.
Treatment of Cough Cough is a useful protective reflex. Cough is an indicator of an underlying illness. Mechanical stimulation of large respiratory passages, OR: Chemical stimulation of alveoli. After
More informationAerosol Therapy. Aerosol Therapy. RSPT 1410 Humidity & Aerosol Therapy Part 4
1 RSPT 1410 Humidity & Part 4 Wilkins Chapter 36; p. 801-806 2 Stability: the tendency for aerosol particles to remain in Size: the the particle, the greater the tendency toward stability the the particle,
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationacapella vibratory PEP Therapy System Maximizing Therapy Effectiveness, Empowering Patient Compliance
acapella vibratory PEP Therapy System Maximizing Therapy Effectiveness, Empowering Patient Compliance Investigating Questions Each acapella vibratory PEP therapy system uniquely provides PEP therapy by
More informationBronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis
Eur Respir J 2002; 20: 122 126 DOI: 10.1183/09031936.02.00264002 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Bronchial reactions to the
More informationHigh Frequency Chest Wall Oscillation Devices
High Frequency Chest Wall Oscillation Devices Policy Number: Original Effective Date: MM.01.007 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 10/24/2014 Section: DME
More informationRespiratory Management- Your Questions Answered! Michelle Chatwin, PhD Consultant Physiotherapist
Respiratory Management- Your Questions Answered! Michelle Chatwin, PhD Consultant Physiotherapist Why Are People Affected Differently Neuromuscular Disease; A Spectrum Its severity varies widely within
More informationClinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages)
Clinical Commissioning Policy Proposition: Dornase alfa inhaled therapy for primary ciliary dyskinesia (all ages) Reference: NHS England E03X05/01 Information Reader Box (IRB) to be inserted on inside
More informationCitation for published version (APA): Schans, C. P. V. D. (1991). Physiotherapy and bronchial mucus transport s.n.
University of Groningen Physiotherapy and bronchial mucus transport van der Schans, Cees P. IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationMedicine Dr. Kawa Lecture 1 Asthma Obstructive & Restrictive Pulmonary Diseases Obstructive Pulmonary Disease Indicate obstruction to flow of air
Medicine Dr. Kawa Lecture 1 Asthma Obstructive & Restrictive Pulmonary Diseases Obstructive Pulmonary Disease Indicate obstruction to flow of air through the airways. As asthma, COPD ( chronic bronchitis
More informationHigh Frequency Chest Wall Oscillating Devices (HFCWO) (Airway Clearance Systems)
High Frequency Chest Wall Oscillating Devices (HFCWO) (Airway Clearance Systems) Date of Origin: 05/2015 Last Review Date: 07/26/2017 Effective Date: 07/26/2017 Dates Reviewed: 07/2016 Developed By: Medical
More informationThe Use of Active Cycle of Breathing Technique (ACBT) In Pulmonary Physiotherapy: A Critical Review of the Literature Lauro G. Villegas Jr.
The Use of Active Cycle of Breathing Technique (ACBT) In Pulmonary Physiotherapy: A Critical Review of the Literature Lauro G. Villegas Jr., PTRP Keywords: Active Cycle of Breathing Technique (ACBT), Pulmonary
More informationEffect of N-Acetylcysteine on Air Trapping in COPD. A Randomized Placebo-Controlled Study
CHEST Effect of N-Acetylcysteine on Air Trapping in COPD A Randomized Placebo-Controlled Study David Stav, MD; and Meir Raz, MD Original Research COPD Background: FEV 1 is used for the classification of
More informationComparison of inhaled mannitol, daily rhdnase, and a combination. of both in children with cystic fibrosis: a randomised trial
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.116970 Comparison of inhaled mannitol, daily rhdnase, and a combination of both in children with cystic fibrosis: a randomised trial
More informationFunction of the Respiratory System. Exchange CO2 (on expiration) for O2 (on inspiration)
Function of the Respiratory System Exchange CO2 (on expiration) for O2 (on inspiration) Upper Respiratory Tract Includes: Nose Mouth Pharynx Larynx Function: Warms and humidifies the inspired air Filters
More informationMucolytics in cystic fibrosis
PAEDIATRIC RESPIRATORY REVIEWS (2007) 8, 24 29 MINI-SYMPOSIUM: AIRWAY CLEARANCE IN CYSTIC FIBROSIS Mucolytics in cystic fibrosis Markus O. Henke 1 and Felix Ratjen 2, * 1 Department of Pulmonary Medicine,
More informationMucomist Respirator Solution, Acetylcysteine USP 200 mg/ ml Solution for inhalation (not for injection)
Mucomist Respirator Solution, Acetylcysteine USP 200 mg/ ml Solution for inhalation (not for injection) DESCRIPTION Mucomist Respirator Solution is a derivative of the amino acid, cysteine. It acts mostly
More information10/05/2017. Learning Objectives. Etiology and Prevalence. Diagnosis of Cystic Fibrosis. Disease of Childhood? Survival in Cystic Fibrosis
Management of the Cystic Fibrosis Patient Jessica Goggin, MAS, RN Nurse Manager UC San Diego Adult Cystic Fibrosis Program Learning Objectives 1. Describe the symptoms associated with Cystic Fibrosis (CF).
More informationTITLE: Hypertonic Saline Nebules for Patients with Cystic Fibrosis and Bronchioectasis: A Review of the Clinical and Cost-Effectiveness
TITLE: Hypertonic Saline Nebules for Patients with Cystic Fibrosis and Bronchioectasis: A Review of the Clinical and Cost-Effectiveness DATE: 16 March 2009 CONTEXT AND POLICY ISSUES: Hypertonic saline
More informationCystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina
Cystic Fibrosis: Progress in Treatment Management Patrick A. Flume, M.D. Medical University of South Carolina Disclosures Grant support Mpex Pharmaceuticals, Inc Gilead Sciences, Inc Bayer Healthcare AG
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationThe role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE
The role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE RHYS JEFFERIES ARTP education Learning Objectives Examine the clinical features of airways disease to distinguish
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 31 Oct 2018 11:13:48 GMT) CTRI Number Last Modified On 17/01/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationRespiratory Therapy. Medical/Scientific/General Background
Respiratory Therapy Medical/Scientific/General Background Marketing Europe Dr. Rainer Jakobs PMM Europe 1 Dr. Rainer Jakobs, PMM Europe RT Medical/Scientific/General Background 2 Dr. Rainer Jakobs, PMM
More informationCYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE
CYSTIC FIBROSIS Madhu Pendurthi MD MPH Staff Physician, Mercy Hospital Springfield, MO NO CONFLICT OF INTEREST TO DISCLOSE OBJECTIVES Epidemiology of Cystic Fibrosis (CF) Genetic basis and pathophysiology
More informationPhysiotherapy in lung disease - top tips for clinicians. Sita Kansagra Specialist Outpatient Physiotherapist
Physiotherapy in lung disease - top tips for clinicians Sita Kansagra Specialist Outpatient Physiotherapist Aims: Run through current physiotherapy practice Airway clearance Pulmonary rehabilitation Dysfunctional
More informationNebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis (Review)
Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis (Review) Nash EF, Stephenson A, Ratjen F, Tullis E This is a reprint of a Cochrane review, prepared and maintained by The Cochrane
More informationCHAPTER 7.1 STRUCTURES OF THE RESPIRATORY SYSTEM
CHAPTER 7.1 STRUCTURES OF THE RESPIRATORY SYSTEM Pages 244-247 DO NOW What structures, do you think, are active participating in the breathing process? 2 WHAT ARE WE DOING IN TODAY S CLASS Finishing Digestion
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More informationHigh Frequency Chest Wall Oscillation Devices
High Frequency Chest Wall Oscillation Devices Policy Number: Original Effective Date: MM.01.007 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/18/2015 Section: DME
More informationActive Cycle of Breathing Technique
Active Cycle of Breathing Technique Full Title of Guideline: Author (include email and role): Division & Speciality: Version: 3 Ratified by: Scope (Target audience, state if Trust wide): Review date (when
More informationAcapella versus usual airway clearance during acute exacerbation in bronchiectasis: a randomized crossover trial
Chronic Respiratory Disease 2007; 4: 67 74 http://crd.sagepub.com ORIGINAL PAPER Acapella versus usual airway clearance during acute exacerbation in bronchiectasis: a randomized crossover trial JE Patterson,
More informationOscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions
Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Conditions Policy Number: 1.01.15 Last Review: 3/2018 Origination: 3/2001 Next Review: 3/2019 Policy Blue Cross and Blue Shield
More informationHyperinflation Therapy and the Tools to Accomplish It!! Bill Barnes, RN, RRT Good Shepherd Rehabilitation Network
Hyperinflation Therapy and the Tools to Accomplish It!! Bill Barnes, RN, RRT Good Shepherd Rehabilitation Network HYPERINFLATION THERAPY Challenges in Post Acute Care Deconditioning Malnutrition Hydration
More informationPatient characteristics Intervention Comparison Length of followup
ORAL MUCOLYTICS Ref ID: 2511 Bachh AA, Shah NN, Bhargava R et al. Effect oral N- in COPD - A randomised controlled trial. JK Practitioner. 2007; 14(1):12-16. Ref ID: 2511 RCT Single blind; unclear allocation
More informationNon-CF bronchiectasis: Alexander Duarte, MD Pulmonary, Critical Care & Sleep Medicine University of Texas Medical Branch Galveston, TX
Non-CF bronchiectasis: Alexander Duarte, MD Pulmonary, Critical Care & Sleep Medicine University of Texas Medical Branch Galveston, TX Pioneer of Respiratory Medicine 2016 marked 200th anniversary of his
More informationDISEASES OF THE RESPIRATORY SYSTEM 2018 DR HEYAM AWAD LECTURE 3: CHRONIC BRNCHITIS AND BRONCHIECTASIS
DISEASES OF THE RESPIRATORY SYSTEM 2018 DR HEYAM AWAD LECTURE 3: CHRONIC BRNCHITIS AND BRONCHIECTASIS INTRDUCTION In the last lecture we discussed the difference between restrictive and obstructive lung
More information